Source:http://linkedlifedata.com/resource/pubmed/id/11036017
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2000-11-2
|
| pubmed:abstractText |
GAR-936, a novel glycylcycline, was investigated with a rat model of experimental endocarditis. It was compared with vancomycin against both vancomycin-susceptible and -resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus. GAR-936 exhibited the lowest MICs (</=0.12 microgram/ml) in vitro against each of the isolates tested. Endocarditis was established by placement of a catheter across the aortic valve, followed by intravenous injection of 10(6) CFU of bacteria 48 h later. Treatment with GAR-936 or vancomycin was initiated 24 to 36 h after bacterial infection and administered subcutaneously twice a day for 3 days at ascending doses. GAR-936 reduced bacterial vegetation titers by >2 log(10) CFU, compared to those in untreated controls, for both vancomycin-susceptible and -resistant (VanA and VanB) E. faecalis strains and >4 log(10) CFU for a methicillin-resistant S. aureus isolate. The glycylcycline was more efficacious at a lower administered dose in the rat model of endocarditis than was vancomycin. The efficacy of GAR-936 in this model was apparently not enhanced by a factor in rat serum, as was observed for vancomycin with a time-kill curve. The results of this study demonstrate the therapeutic potential of GAR-936 for the treatment of enterococcal and staphylococcal infections and warrant further investigation.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-10103174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-1416824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-1444286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-1903800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-2501270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-417032,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-6490570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-7492078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-7492108,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-7695248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-8203835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-8335526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11036017-8619584
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0066-4804
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3022-7
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:11036017-Animals,
pubmed-meshheading:11036017-Anti-Bacterial Agents,
pubmed-meshheading:11036017-Disease Models, Animal,
pubmed-meshheading:11036017-Endocarditis, Bacterial,
pubmed-meshheading:11036017-Enterococcus faecalis,
pubmed-meshheading:11036017-Male,
pubmed-meshheading:11036017-Microbial Sensitivity Tests,
pubmed-meshheading:11036017-Minocycline,
pubmed-meshheading:11036017-Rats,
pubmed-meshheading:11036017-Rats, Wistar
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.
|
| pubmed:affiliation |
Infectious Disease Research Section, Antimicrobial Chemotherapy, Wyeth-Ayerst Research, Pearl River, New York 10965, USA. murphytm@war.wyeth.com
|
| pubmed:publicationType |
Journal Article
|